TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
Other Report or Announcement
Scage Future Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Contango Announces Results of the 2026 Virtual Annual Meeting of Stockholders
Comstock Appoints former Blackstone and Citigroup Leader David Hirsh to Board of Directors
BTQ TECHNOLOGIES ANNOUNCES AT-THE-MARKET EQUITY PROGRAM
UTHR: Notification
UTHR: Notification
Centrus Energy Corp. Announces Extension of Section 382 Rights Agreement
UniFirst Corporation Plans to Announce Third Quarter Results on July 1, 2026